1. Volume 394, Issue 10193, Pages 148-158 (July 2019)
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study 
Prof Pierre Van Damme, PhD, Ilse De Coster, MD, Ananda S Bandyopadhyay, MBBS, Hilde Revets, PhD, Kanchanamala Withanage, PhD, Philippe De Smedt, MD, Leen Suykens, MSc, M Steven Oberste, PhD, William C Weldon, PhD, Sue Ann Costa-Clemens, MD, Ralf Clemens, MD, John Modlin, MD, Amy J Weiner, PhD, Andrew J Macadam, PhD, Prof Raul Andino, PhD, Olen M Kew, PhD, Jennifer L Konopka-Anstadt, PhD, Cara C Burns, PhD, John Konz, PhD, Rahnuma Wahid, PhD, Christopher Gast, PhD 
The Lancet 
Volume 394, Issue 10193, Pages (July 2019)
DOI: /S (19)
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3. Figure 2
Viral shedding of the two novel oral type-2 poliovirus vaccine candidates
Data are the number of PCR-positive stool samples and the log10(CCID50/g) after administration on day 0. Participants who had ceased shedding were included, at a value of 0, in the computation of the mean log10(CCID50/g). CCID50=50% cell culture infectious dose.
The Lancet  , DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions